ES557016A0 - Procedimiento para la obtencion de celulas de hibridona que disocian anticuerpos monoclonales con elevada afinidad a la renina humana. - Google Patents

Procedimiento para la obtencion de celulas de hibridona que disocian anticuerpos monoclonales con elevada afinidad a la renina humana.

Info

Publication number
ES557016A0
ES557016A0 ES557016A ES557016A ES557016A0 ES 557016 A0 ES557016 A0 ES 557016A0 ES 557016 A ES557016 A ES 557016A ES 557016 A ES557016 A ES 557016A ES 557016 A0 ES557016 A0 ES 557016A0
Authority
ES
Spain
Prior art keywords
human
monoclonal antibodies
high affinity
hybridone
disounce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES557016A
Other languages
English (en)
Other versions
ES8802254A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES8802254A1 publication Critical patent/ES8802254A1/es
Publication of ES557016A0 publication Critical patent/ES557016A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/86—Renin inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
ES557016A 1984-04-09 1986-08-14 Procedimiento para la obtencion de celulas de hibridona que disocian anticuerpos monoclonales con elevada afinidad a la renina humana. Expired ES8802254A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH178184 1984-04-09

Publications (2)

Publication Number Publication Date
ES8802254A1 ES8802254A1 (es) 1988-04-16
ES557016A0 true ES557016A0 (es) 1988-04-16

Family

ID=4218460

Family Applications (2)

Application Number Title Priority Date Filing Date
ES542017A Expired ES8707295A1 (es) 1984-04-09 1985-04-08 Procedimiento para la obtencion de anticuerpos monoclonales
ES557016A Expired ES8802254A1 (es) 1984-04-09 1986-08-14 Procedimiento para la obtencion de celulas de hibridona que disocian anticuerpos monoclonales con elevada afinidad a la renina humana.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES542017A Expired ES8707295A1 (es) 1984-04-09 1985-04-08 Procedimiento para la obtencion de anticuerpos monoclonales

Country Status (13)

Country Link
US (1) US4780401A (es)
EP (1) EP0158599B1 (es)
JP (2) JPH0669390B2 (es)
AT (1) ATE57392T1 (es)
AU (1) AU591870B2 (es)
CA (1) CA1277261C (es)
DE (1) DE3580056D1 (es)
DK (1) DK165326C (es)
ES (2) ES8707295A1 (es)
FI (1) FI87933C (es)
IE (1) IE57956B1 (es)
NO (1) NO165556C (es)
ZA (1) ZA852557B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
WO1993023433A1 (en) * 1992-05-14 1993-11-25 L.R.S. Diagnostics, Inc. Methods and novel proteins associated with low renin syndrome
DE606516T1 (de) * 1993-01-13 1995-03-16 Idemitsu Kosan Co Gegen menschlichen Ceruloplasmin monoklonaler Antikörper.
WO1994020857A1 (en) * 1993-03-11 1994-09-15 The Regents Of The University Of California Assay for humoral immunity to macromolecules
US6911528B1 (en) * 1994-12-02 2005-06-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US20030167483A1 (en) * 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
WO2002048715A2 (en) 2000-12-14 2002-06-20 The Brigham And Women's Hospital, Inc. Inflammatory markers for detection and prevention of diabetes mellitus
ATE534747T1 (de) 2002-05-09 2011-12-15 Brigham & Womens Hospital 1l1rl-1 als marker für kardiovaskuläre erkrankungen
US7273616B2 (en) * 2002-05-10 2007-09-25 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
JP2007502831A (ja) * 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
EP1668008A4 (en) * 2003-08-28 2009-02-25 Nitromed Inc NITROSED AND NITROSYLATED DIETETIC COMPOUNDS, COMPOSITIONS AND APPLICATION METHODS
HUE027546T2 (en) 2003-08-29 2016-10-28 Brigham & Womens Hospital Inc Hydantoin derivatives as cell necrosis inhibitors
US7781219B2 (en) 2003-12-05 2010-08-24 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
EP1718286A4 (en) * 2004-01-22 2010-03-31 Nicox Sa NITROSIS AND / OR NITROSYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
US9164104B2 (en) 2004-10-06 2015-10-20 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
WO2006055542A2 (en) * 2004-11-15 2006-05-26 Nitromed, Inc. Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
WO2006078995A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
WO2006083779A2 (en) * 2005-01-31 2006-08-10 Mylan Laboratories, Inc. Pharmaceutical composition comprising hydroxylated nebivolol
AU2006336387A1 (en) * 2005-02-16 2007-08-02 Nicox S.A. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
AU2006218766A1 (en) * 2005-02-28 2006-09-08 Nicox S.A. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
EP1861093A2 (en) * 2005-03-09 2007-12-05 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
EP2808015A1 (en) 2005-05-31 2014-12-03 Mylan Laboratories, Inc Compositions comprising nebivolol
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
CA2624933A1 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. Methods for treating respiratory disorders
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
EP1954685A4 (en) * 2005-11-16 2009-11-11 Nitromed Inc FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
US20090053328A1 (en) * 2005-12-20 2009-02-26 Nitromed, Inc. Nitric Oxide Enhancing Glutamic Acid Compounds, Compositions and Methods of Use
US20080293702A1 (en) * 2005-12-22 2008-11-27 Nitromed, Inc. Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
US7897360B2 (en) * 2006-12-15 2011-03-01 Kimberly-Clark Worldwide, Inc. Enzyme detection techniques
DK2147315T3 (da) 2007-04-18 2013-09-23 Tethys Bioscience Inc Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
SG182821A1 (en) 2010-02-01 2012-08-30 Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
AU2011234189B2 (en) 2010-03-31 2015-12-03 The Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
CN107674071B (zh) 2012-05-11 2021-12-31 同步制药公司 作为隐花色素调节剂的含有咔唑的磺酰胺类
PT2879666T (pt) 2012-08-01 2020-05-07 Tavakoli Zahra Composições congeladas, de fluxo livre contendo um agente terapêutico
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2018074455A1 (ja) * 2016-10-21 2018-04-26 富士レビオ株式会社 レニン濃度の免疫学的測定法
CN107007849A (zh) * 2017-06-19 2017-08-04 河北省人民医院 一种建立甲减性心功能不全大鼠动物模型的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies

Also Published As

Publication number Publication date
FI851334A0 (fi) 1985-04-03
AU4088685A (en) 1985-10-17
DK153385D0 (da) 1985-04-03
EP0158599A3 (en) 1987-12-16
DK153385A (da) 1985-10-10
DE3580056D1 (de) 1990-11-15
EP0158599A2 (de) 1985-10-16
CA1277261C (en) 1990-12-04
ES8802254A1 (es) 1988-04-16
ES8707295A1 (es) 1987-07-16
IE850876L (en) 1985-10-09
FI851334L (fi) 1985-10-10
FI87933C (fi) 1993-03-10
NO851384L (no) 1985-10-10
JPS60231624A (ja) 1985-11-18
DK165326C (da) 1993-03-29
DK165326B (da) 1992-11-09
ATE57392T1 (de) 1990-10-15
AU591870B2 (en) 1989-12-21
ES542017A0 (es) 1987-07-16
JPS6485070A (en) 1989-03-30
JPH0669371B2 (ja) 1994-09-07
NO165556C (no) 1991-02-27
US4780401A (en) 1988-10-25
FI87933B (fi) 1992-11-30
ZA852557B (en) 1985-11-27
NO165556B (no) 1990-11-19
EP0158599B1 (de) 1990-10-10
IE57956B1 (en) 1993-05-19
JPH0669390B2 (ja) 1994-09-07

Similar Documents

Publication Publication Date Title
ES557016A0 (es) Procedimiento para la obtencion de celulas de hibridona que disocian anticuerpos monoclonales con elevada afinidad a la renina humana.
DE3854194D1 (de) Monoklonale antikörper gegen glykosyliertes albumin, hybride zellinien, die diese antikörper produzieren, sowie deren verwendung.
FI840219A0 (fi) Human-humanhybridom foer neoplasmer
ES557072A0 (es) Procedimiento para la obtencion de lineas celulares de hibridoma
DE3378414D1 (en) Protein (pp13), process for concentrating and obtaining it, and its use
ES553154A0 (es) Un procedimiento para la obtencion de anticuerpos monoclonales contra peptidos atriales natuureticos.
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
SE8404334D0 (sv) 16-fluoro-16,17-didehydro-prostanoids and process for their preparation
FI874273A (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
ES552705A0 (es) Procedimiento inmunologico para la determinacion de la hormona estimuladora de foliculos
EP0248147A3 (en) Method of determining the presence of cancer cells
FI931988A (fi) Menetelmä terapeuttisesti aktiivisten fosfopeptidien valmistamiseksi

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20001102